Boeing to showcase cutting-edge solutions at Idex
'IDEX is a key opportunity to engage with partners across the region and showcase how our advanced defense solutions can support the country's security and aerospace ambitions,' said Kuljit Ghata-Aura, President of Boeing Middle East, Türkiye, Africa, and Central Asia.
'Our commitment to the UAE spans more than four decades, and we look forward to deepening collaboration through pioneering industrial and technological initiatives and further contributing to the growing domestic defense industrial base.'
At IDEX 2025, among the products being highlighted include:
• T-7 Advanced Trainer – Next-generation pilot training system with fighter-like performance.
• AH-64 Apache – Advanced, combat-proven attack helicopter, evolving for continued battlefield dominance.
• CH-47 Chinook – Multi-mission heavy-lift helicopter with advanced digital cockpit and cargo handling capabilities.
• F-15EX – The backbone of tactical fighter fleets with increased payload capacity, advanced electronic warfare system and the world's most powerful fighter radar.
• Insitu Integrator ER – Long-range uncrewed system for intelligence, surveillance, and reconnaissance.
Boeing will also showcase its services portfolio, including performance-based logistics support, parts, modifications and modernization, upgrades, and training. These offerings are designed to support the defense modernization and mission readiness of customers in the UAE and the Middle East.
Boeing has been a trusted partner of the UAE Government since 1978, providing and sustaining advanced defense platforms, including the AH-64 Apache, CH-47 Chinook, and C-17 Globemaster III. These aircraft play a vital role in protecting the UAE's air, land, and sea borders and supporting global humanitarian missions.
As a leading global aerospace company, Boeing develops, manufactures and services commercial airplanes, defense products and space systems for customers in more than 150 countries. As a top US exporter, the company leverages the talents of a global supplier base to advance economic opportunity, sustainability and community impact.
Boeing's team is committed to innovating for the future, leading with sustainability, and cultivating a culture based on the company's core values of safety, quality and integrity. Boeing's relationship with the Middle East extends back to 1945. Since then, Boeing has established several offices across the region including in Abu Dhabi, Dubai, Doha, Kuwait, and Riyadh, a statement said. -
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Tribune
a day ago
- Daily Tribune
New hope for patients with less common breast cancer
A new treatment nearly halves the risk of disease progression or death from a less common form of breast cancer that hasn't seen major drug advances in over a decade, researchers reported Monday. Results from the study, presented at the annual meeting of the American Society for Clinical Oncology, are expected to be submitted to regulators and could soon establish a new firstline therapy for people with HER2-positive metastatic breast cancer -- the advanced stage of a form that comprises 15–20% of all breast cancer cases. HER2-positive cancers are fueled by an overactive HER2 gene, which makes too much of a protein called human epidermal growth factor receptor 2 that helps cancer cells grow and spread. Patients with HER2-positive breast cancer that has spread to other parts of the body live around five years. 'Seeing such a striking improvement was really impressive to us -- we were taking a standard and almost doubling how long patients could have their cancer controlled for,' oncologist Sara Tolaney, chief of the breast oncology division at Dana-Farber Cancer Institute, told AFP. The current standard of care, known as THP, combines chemotherapy with two antibodies that block growth signals from the HER2 protein. The new approach uses a drug called trastuzumab deruxtecan (T-DXd), an antibody attached to a chemotherapy drug. 'Smart bomb' This 'smart bomb' strategy allows the drug to target cancer cells directly. 'You can bind to the cancer cell and dump all that chemo right into the cancer cells,' explained Tolaney. 'Some people call them smart bombs because they're delivering chemo in a targeted fashion -- which is how I think we're able to really increase efficacy so much.' Common side effects included nausea, diarrhea and a low white blood cell count, with a less common effect involving lung scarring. T-DXd is already approved as a 'second-line' option -- used when first-line treatments stop working. But in the new trial, it was given earlier, paired with another antibody, pertuzumab. In a global trial led by Tolaney, just under 400 patients were randomly assigned to receive T-DXd in combination with pertuzumab, thought to enhance its effects. A similar number received the standard THP regimen. A third group, who received T-DXd without pertuzumab, was also enrolled -- but those results haven't yet been reported. 44 percent risk reduction At a follow-up of 2.5 years, the T-DXd and pertuzumab combination reduced the risk of disease progression or death by 44% compared to standard care. Fifteen percent of patients in the T-DXd group saw their cancer disappear entirely, compared to 8.5% in the THP group. Because this was an interim analysis, the median progression-free survival -- meaning the point at which half the patients had seen their cancer return or worsen -- was 40.7 months with the new treatment, compared to 26.9 months with the standard, and could rise further as more data come in. Tolaney said the results would be submitted to regulators around the world, including the US Food and Drug Administration, and that future work would focus on optimizing how long patients remain on the treatment, particularly those showing complete remission. 'This represents a new firstline standard treatment option for HER2-positive metastatic breast cancer,' said Dr. Rebecca Dent, a breast cancer specialist at the National Cancer Center Singapore who was not involved in the study.
Biz Bahrain
28-05-2025
- Biz Bahrain
CBB Government Development Bond issue 40 oversubscribed by 203%
The Central Bank of Bahrain (CBB) announces that the issue of the 3-year Government Development Bond has been oversubscribed by 203%. Subscriptions worth BD 507.802 million were received for the BD 250 million issue, which carries a maturity of 3 years. The fixed annual coupon rate on the issue, which begins on May 29 and matures on May 29, 2028, is 6.125%. The Government Development Bonds are issued by the CBB on behalf of the Government of the Kingdom of Bahrain. This is Government Development Bond issue No.40 (ISIN BH00010U5465).
Daily Tribune
26-05-2025
- Daily Tribune
US, Boeing reach deal to resolve MAX criminal case
The Justice Department said Friday it reached a preliminary agreement with Boeing to settle a long-running criminal probe into deadly 737 MAX crashes, drawing condemnation from some crash victim families. Under an 'agreement in principle,' Boeing will pay $1.1 billion and the Department of Justice (DOJ) would dismiss a criminal charge against Boeing over its conduct in the certification of the MAX, DOJ said in a federal filing. A judge must approve the accord, which would scuttle a criminal trial scheduled for June in Fort Worth, Texas. The agreement would resolve the case without requiring Boeing to plead guilty to fraud in the certification of the MAX, which was involved in two crashes in 2018 and 2019 that claimed 346 lives. Family members of some MAX victims slammed the proposed settlement as a giveaway to Boeing. 'The message sent by this action to companies around the country is, don't worry about making your products safe for your customers,' said Javier de Luis in a statement released by attorneys for plaintiffs suing Boeing. 'This kind of non-prosecution deal is unprecedented and obviously wrong for the deadliest corporate crime in US history,' said Paul Cassell, an attorney representing relatives of victims. 'My families will object and hope to convince the court to reject it.' But the DOJ, in its brief, cited other family members who expressed a desire for closure, quoting one who said 'the grief resurfaces every time this case is discussed in court or other forums.' Family members of more than 110 crash victims told the government 'they either support the Agreement specifically, support the Department's efforts to resolve the case pre-trial more generally or do not oppose the agreement,' the filing said. The DOJ filing called the accord 'a fair and just resolution that serves the public interest.' 'The Agreement guarantees further accountability and substantial benefits from Boeing immediately, while avoiding the uncertainty and litigation risk presented by proceeding to trial,' it said. Friday's proposed agreement marks the latest development in a marathon case that came in the wake of the two crashes that tarnished Boeing's reputation and contributed to leadershipshakeups at the aviation giant. The case dates to a January 2021 DOJ agreement with Boeing that settled charges that the company knowingly defrauded the Federal Aviation Administration during the MAX certification. The 2021 accord included a three-year probation period. But in May 2024, the DOJ determined that Boeing had violated the 2021 accord following a number of subsequent safety lapses.
